Interrogating informality: Conceptualisations, practices and policies in the light of the New Urban Agenda

Informality is growing in a context of increasing inequity, and in many places becoming the norm. However, despite decades of studies and interventions, ‘recognising informality’ is still a key issue. This paper provides a review of the literature on informality showing the shifts in its conceptualisations. The paper firstly discusses conceptual approaches related to the term ‘informality’ in the context of urban development; it then examines practices within, and related to, informality; and it concludes with an appraisal of policy approaches and their impact as reported in the literature. The paper finds a wide range of conceptualisations, including the questioning of the usefulness and appropriateness of the term. It finds reported evidence of ‘informality’ (as understood to date) spreading to the middle classes, and increasingly emerging in the Global North. Policies seem to be lagging behind in how they engage with so-called informality, with little acknowledgement of theory and limited understanding of their impacts on ‘informal’ practices. Finally, the paper identifies the need for better understanding of governance frameworks that include the range of actors that would normally be associated with so-called ‘informality’

Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV

BACKGROUND: As antiretroviral treatment (ART) for HIV/AIDS is scaled-up globally, information on per-person costs is critical to improve efficiency in service delivery and maximize coverage and health impact. OBJECTIVE: To review studies on delivery unit costs for adult and pediatric ART provision per-patient-year, and prevention of mother-to-child transmission (PMTCT) interventions per mother-infant pair screened or treated, in low- and middle-income countries. METHODS: Systematic review of English, French and Spanish publications from 2001 to 2009, reporting empirical costing that accounted for at least antiretroviral (ARV) medicines, laboratory testing and personnel. Expenditures were analyzed by country income level and cost component. All costs were standardized to 2009 US dollars. RESULTS: Analyses covered 29 eligible, comprehensive costing studies. In the base case, in low-income countries (LIC), median, ART cost per patient-year was $792 (mean:$839, range: $682-$1089); for lower-middle-income countries (LMIC), the median was $932 (mean:$1246, range: $156-$3904); and for upper-middle-income countries (UMIC) the median was $1454 (mean:$2783, range: $1230-$5667). ARV drugs were largest component of overall ART cost in all settings (62%, 50% and 47% in LIC, LMIC and UMIC respectively). Out of 26 ART studies, 14 report which drug regimes were used, and only one study explicitly reported second line treatment costs. The second cost driver was laboratory cost in LIC and LMIC (14% and 19.5%) whereas it was personnel costs in UMIC (26%). Two studies specified the types of laboratory tests costed, and three studies specifically included above-facility-level personnel costs. Three studies reported detailed PMTCT costs, and two studies reported on pediatric ART. CONCLUSIONS: There is a paucity of data on the full ART and PMTCT delivery unit costs, in particular for low-and middle-income countries. Heterogeneity in activities costed and insufficient detail regarding components included in the costing hampers standardization of unit cost measures. Evaluation of program-level unit costs would benefit from international guidance on standardized costing methods, and expenditure categories and definitions. Future work should help elucidate the sources for the large variations in delivery unit costs across settings with similar income and epidemiological characteristics